Medtronic plc affirmed its Q2 dividend of $0.71 per share and focused on expanding its PFA technology using the Hugo robotic platform for hypertension treatment.
2 reports, 1 independent
Updated Sep 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medtronic plc affirmed its Q2 dividend of $0.71 per share and focused on expanding its PFA technology using the Hugo robotic platform for hypertension treatment.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Corporate activity in the medical device sector in August 2025 included M&A activity (Stryker/Inari Medical, ZimVie/Archimed), competition between Medtronic and Intuitive Surgical, and the impact of Trump administration tariffs and FDA reviews.Also in this story
- FDA approved Medtronic's Hugo robotic system for urological procedures, marking a major competitive shift in the medical device sector.
- Market sentiment regarding growth rates turned disappointing for companies like Profound Medical on August 1, 2025.
- Medtronic is developing a robotic-assisted surgery system that needs regulatory approval in the US, amidst aggressive trade policy threats.
- Lemaitre, Intuitive Surgical, and Teleflex are identified as companies operating in the surgical equipment segment.
The entities involved
Coverage
Newest first; wire copies grouped- Simply Wall St.Medtronic (MDT) Declares US$0.71 Dividend Confirming 48 Years Of Increases Medtronic has recently affirmed a Q2 dividend of $0.71 per share, which aligns with its commitment to long-standing dividend